Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Fred Hutchinson Cancer Center
University of Colorado, Denver
City of Hope Medical Center
Barbara Ann Karmanos Cancer Institute
Novartis
Var2 Pharmaceuticals
City of Hope Medical Center
UNC Lineberger Comprehensive Cancer Center
A2 Biotherapeutics Inc.
University of California, San Francisco
ModeX Therapeutics, An OPKO Health Company
Columbia University
University of Arizona
Esperas Pharma Inc.
Stanford University
Stanford University
Northwestern University
Hutchmed
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Chongqing Precision Biotech Co., Ltd
National Cancer Institute (NCI)
Corvus Pharmaceuticals, Inc.
Chongqing Precision Biotech Co., Ltd
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Klus Pharma Inc.
Eastern Cooperative Oncology Group
Qianfoshan Hospital
Institut de Cancérologie de Lorraine
Uppsala University
Novartis
MacroGenics
Wake Forest University Health Sciences
Gilead Sciences
Jerome Canady Research Institute for Advanced Biological & Technological Sciences
Institut Bergonié
Abramson Cancer Center at Penn Medicine
Ohio State University Comprehensive Cancer Center
Abramson Cancer Center at Penn Medicine
Fox Chase Cancer Center
SWOG Cancer Research Network
University Hospital Tuebingen
Stanford University
Centre Antoine Lacassagne
Radboud University Medical Center
Montefiore Medical Center
Johns Hopkins Bloomberg School of Public Health
Johns Hopkins Bloomberg School of Public Health
Northwestern University
Duke University